LETERMOVIR PRIMARY AND SECONDARY PROPHYLAXIS IN PEDIATRIC RECIPIENTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT. (PubMed, Transplant Cell Ther) - May 29, 2025 - "Letermovir is safe and efficacious in preventing CMV reactivation in pediatric patients undergoing HSCT in both primary and secondary prophylaxis."
Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Pediatrics • Transplantation
|
|
Adriana Balduzzi; Francesca Romani; Francesca Vendemini; Giovanna Lucchini; Maria Grazia Valsecchi; Marta Verna; Paola De Lorenzo; Sandro Maria Ivano Malandrin; Sonia Bonanomi
|